How does PHRX's PB Ratio compare to its peers?

PHRX has negative equity and a Price-To-Book Ratio (-1.1x) compared to the peer average (0.5x).

How does PHRX's PB Ratio compare vs other companies in the CA Pharmaceuticals Industry?

PHRX has negative equity and a Price-To-Book Ratio (-1.1x) compared to the Canadian Pharmaceuticals industry average (1.1x).

What is PHRX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate PHRX's Price-To-Book Fair Ratio for valuation analysis.

What is the Fair Price of PHRX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate PHRX's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Pharmadrug (CNSX:PHRX) - Stock Price, News & Analysis

PHRX Stock Overview

Operates as a specialty pharmaceutical company. More details

PHRX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Risk Analysis

Earnings have declined by 16.7% per year over past 5 years

Does not have a meaningful market cap (CA$2M)

Makes less than USD$1m in revenue (CA$0)

Negative shareholders equity

+ 2 more risks

Pharmadrug Inc. Competitors

TILT Holdings

NEOE:TILT

CA$3.9m

Algernon Pharmaceuticals

CNSX:AGN

CA$2.2m

Steep Hill

CNSX:STPH

CA$323.6k

RAMM Pharma

CNSX:RAMM

CA$1.8m

Price History & Performance

Summary of all time highs, changes and price drops for Pharmadrug
Historical stock prices
Current Share Price	CA$0.015
52 Week High	CA$0.075
52 Week Low	CA$0.005
Beta	2.69
11 Month Change	-40.00%
3 Month Change	-25.00%
1 Year Change	-62.50%
33 Year Change	-94.64%
5 Year Change	-92.86%
Change since IPO	-99.67%

Recent updates

Shareholder Returns

	PHRX	CA Pharmaceuticals	CA Market
7D	0%	-6.9%	2.2%
1Y	-62.5%	-22.8%	23.4%

Return vs Industry: PHRX underperformed the Canadian Pharmaceuticals industry which returned -23.2% over the past year.

Return vs Market: PHRX underperformed the Canadian Market which returned 23.4% over the past year.

Price Volatility

Is PHRX's price volatile compared to industry and market?
PHRX volatility
PHRX Average Weekly Movement	39.6%
Pharmaceuticals Industry Average Movement	12.0%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.7%
10% least volatile stocks in CA Market	2.9%

Stable Share Price: PHRX's share price has been volatile over the past 3 months compared to the Canadian market.

Volatility Over Time: PHRX's weekly volatility has decreased from 46% to 40% over the past year, but is still higher than 75% of Canadian stocks.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Robert Steen	www.pharmadrug.ca

Pharmadrug Inc. operates as a specialty pharmaceutical company. It focuses on the research, development, and commercialization of controlled-substances and natural medicines, such as psychedelics, cannabis, and naturally derived approved drugs. The company also engages in the researching and reformulating of established natural medicines; development of synthetic formulations of existing drugs for potential commercialization and distribution; development of cepharanthine, a drug for the treatment of infectious disease and rare cancers; and research and development activities in the psychedelics space for the treatment of non-neuropsychiatric conditions.

Pharmadrug Inc. Fundamentals Summary

How do Pharmadrug's earnings and revenue compare to its market cap?
PHRX fundamental statistics
Market cap	CA$1.62m
Earnings (TTM)	-CA$13.17m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Is PHRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHRX income statement (TTM)
Revenue	CA$0
Cost of Revenue	CA$0
Gross Profit	CA$0
Other Expenses	CA$13.17m
Earnings	-CA$13.17m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.12
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-107.3%

How did PHRX perform over the long term?

See historical performance and comparison

PHRX Stock Overview

Risk Analysis

Pharmadrug Inc. Competitors

NEOE:TILT

CA$3.9m

CNSX:AGN

CA$2.2m

CNSX:STPH

CA$323.6k

CNSX:RAMM

CA$1.8m

Price History & Performance

Recent News & Updates

New major risk - Financial position

New major risk - Negative shareholders equity

PharmaDrug Inc Announces Board Changes

Pharmadrug Inc. announced that it has received CAD 0.326 million in funding

Pharmadrug Inc. announced that it expects to receive CAD 0.326 million in funding

New major risk - Shareholder dilution

Recent updates

New major risk - Financial position

New major risk - Negative shareholders equity

PharmaDrug Inc Announces Board Changes

Pharmadrug Inc. announced that it has received CAD 0.326 million in funding

Pharmadrug Inc. announced that it expects to receive CAD 0.326 million in funding

New major risk - Shareholder dilution

New minor risk - Shareholder dilution

Pharmadrug Inc. (CNSX:PHRX) completed the acquisition of Securedose Synthetics Inc.

Pharmadrug Inc. (CNSX:PHRX) entered into a definitive agreement to acquire Securedose Synthetics Inc. for CAD 1.1 million.

Pharmadrug Inc. Announces CFO Changes

Pharmadrug Inc. Announces CFO Changes

PharmaDrug Inc. Provides Development Update of Cepharanthine (PD-001) for Cancer and Infectious Disease

PharmaDrug Inc. Announces CEO Changes

Pharmadrug Inc., Annual General Meeting, Oct 23, 2023

New minor risk - Shareholder dilution

PharmaDrug Inc. Announces Plans for First-In-Human Clinical Study with PD-001 (Enteric-Coated Cepharanthine -2HCL) in Esophageal Cancer

PharmaDrug Advances Programs in Oncology with Filing of Patent Cooperation Treaty Application Detailing the Use of PD-001 for Treatment of Prostate Cancer

Third quarter 2022 earnings released: CA$0.009 loss per share (vs CA$0.004 loss in 3Q 2021)

High number of new and inexperienced directors

Pharmadrug Inc., Annual General Meeting, Nov 22, 2022

Second quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.002 loss in 2Q 2021)

PharmaDrug Advances Psychedelics Pharmaceutical Program Focused on DMT and DMT Analogues

PharmaDrug Completes Key Milestone to Support cGMP Production of Clinical Lead Candidate PD-001

Pharmadrug Inc. announced that it expects to receive CAD 0.65 million in funding

Pharmadrug Inc. Announces Positive Findings for the Combination of Cepharanthine and Frontline Chemotherapy for IND-Enabling Esophageal Cancer Study

First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 1Q 2021)

Khiron Life Sciences Corp. (TSXV:KHRN) entered into an agreement to acquire Pharmadrug Production GmbH from Pharmadrug Inc. (CNSX:PHRX) for $1.82 Million.

Pharmadrug Inc. announced a financing transaction

Full year 2021 earnings released: CA$0.017 loss per share (vs CA$0.036 loss in FY 2020)

High number of new and inexperienced directors

Pharmadrug Inc. Provides an Update on Multiple Activities Currently Underway Which Support the Company's 'Pipeline-In-A-Pill' Approach in the Development of PD-001

Pharmadrug Inc. Receives Positive Results for DMT-Analogue Program to Treat Glaucoma

PharmaDrug Inc. Announces Filing of US Provisional Patent for Cepharanthine to Treat Prostate Cancer

PharmaDrug Inc. Announces Initiation of Manufacturing of Cepharanthine (PD-001) for Clinical Programs in Rare Cancers and COVID-19

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Pharmadrug Inc. Announces That Its Super Smart Division Is Launching Its Own Premium Blend of Functional Mushrooms

Second quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.017 loss in 2Q 2020)

PharmaDrug Inc. Reports Positive Preclinical Study Results of Cepharanthine to Treat Cancers

Pharmadrug Inc. Advances Product and Clinical Development of Cepharanthine to Treat Infectious Diseases Including Covid-19

Pharmadrug Inc. Announces its Supersmart Launches Psilocybin Online Retail Platform in the Netherlands

First quarter 2021 earnings released: CA$0.006 loss per share (vs CA$0.002 loss in 1Q 2020)

PharmaDrug's Super Smart Launches Online Retail Platform in the United States

PharmaDrug Inc. Initiates Preclinical Study of Cepharanthine to Both Broaden Its Cancer Scope and to Streamline Its Strategy for Esophageal Cancer

Full year 2020 earnings released: CA$0.037 loss per share (vs CA$0.09 loss in FY 2019)

PharmaDrug Inc.'s Sariyo Therapeutics Inc. Appoints Yelena Y. Janjigian to Newly-Formed Scientific and Clinical Advisory Board

PharmaDrug Appoints Steven A. Barker to Its Scientific Advisory Board for Psychedelic Pharmaceuticals

Pharmadrug Inc. (CNSX:BUZZ) completed the acquisition of Sairiyo Therapeutics Inc.

Pharmadrug Inc., Annual General Meeting, Mar 25, 2021

Pharmadrug Inc. (CNSX:BUZZ) entered into a binding letter of intent to acquire Sairiyo Therapeutics Inc. for CAD 5.3 million.

CEO & Chairman exercised options and sold CA$149k worth of stock

CEO & Chairman recently sold CA$196k worth of stock

Third quarter 2020 earnings released: CA$0.005 loss per share

Third quarter 2020 earnings released: CA$0.005 loss per share

Pharmadrug Inc. announced that it has received CAD 0.02 million in funding

Red Light Holland Reaches Distribution Agreement for iMicrodose Packs with Super Smart

Pharmadrug Inc. announced that it has received CAD 0.2 million in funding from Red Light Holland Corp.

Shareholder Returns

Price Volatility

About the Company

Pharmadrug Inc. Fundamentals Summary